Sphere Fluidics expands into additional facility
New offices at leading science hub support the company’s rapid growth following recent investment.
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the company’s accelerated expansion and accommodate its plans for further growth.
Sphere Fluidics recently closed a $4.8 million (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine Single Cell Analysis System. Sphere Fluidics sales, marketing, finance and operations teams join the specialist skills pool at Granta Park, one of the UK’s leading life-science research parks, positioned within the Cambridge Science Cluster, taking 1,038 sq. ft in the McClintock Building. The Park is home to over 2,500 people and multiple organizations, placing the company in close proximity to high-quality research and commercialization activity, and opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.
Sphere Fluidics’ new facilities at Granta Park are in addition to its offices at Babraham Research Campus, Cambridgeshire, UK and Monmouth Junction, New Jersey, USA. The company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia and Korea.
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance